• Overview
  • Eligibility
  • More info
  • Locations

A Phase II Study of Thalidomide and Cyclophosphamide in Patients With Recurrent or Refractory Malignancies (NCT00003754)

National Cancer Institute (NCI)
RATIONALE: Thalidomide may kill tumor cells by stopping the growth of new blood vessels to the tumor. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining thalidomide with chemotherapy may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combining thalidomide and cyclophosphamide in treating children who have recurrent or refractory childhood cancers.
  • Drug: cyclophosphamide
    • Drug: thalidomide
      Ages eligible for Study
      Genders eligible for Study
      Accepts Healthy Volunteers
      OBJECTIVES: I. Determine the efficacy and toxic effects of thalidomide and cyclophosphamide in patients with recurrent or refractory pediatric malignancies.

      OUTLINE: Patients receive oral thalidomide 4 times daily. Cyclophosphamide is administered IV over 1 hour once every 4 weeks, beginning on the same day as thalidomide. Treatment continues in the absence of unacceptable toxicity or disease progression. Tumor response is assessed every 3 months.

      PROJECTED ACCRUAL: A total of 45-80 patients will be accrued for this study within 2 years.

      1 locations

      United States (1)
      • Memorial Sloan-Kettering Cancer Center
        Not specified
        New York, New York, United States, 10021
      31 August, 1998
      23 June, 2013
      A girl giving information about available additional trials.

      FindMeCure helps you find, understand and join clinical trials from all over the world.

      There are more clinical trials for your condition!